NCT06741072 2026-01-08
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
Clinical Trials
9 trialsNCT06252584 2024-02-09
AML-VAC-XS15
University Hospital Tuebingen
Phase 1 Not yet recruiting
NCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00972309 2022-10-12
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00471471 2017-06-22
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
University of Pittsburgh
Phase 1 Completed
NCT00624182 2015-06-23
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer
Akita University Hospital
Phase 1 Suspended
NCT01989559 2015-01-26
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00845611 2012-04-06
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer
Kinki University
Phase 1 Completed